← Back
Data updated: Jun 28, 2026
VIELA BIO
Biotech Pharmaceuticals
VIELA BIO is a biotechnology company with 1 FDA-approved products.
2020
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
FDA Novel Drug Designations
(2020) 1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough
See 1 novel approval →
VIELA BIO's Key Drugs
VIELA BIO's core commercial portfolio centers on UPLIZNA — its most strategically important drugs approved in the last 15 years.
VIELA BIO's Recent FDA Approvals
New NDA/BLA approvals for VIELA BIO over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
VIELA BIO's Therapeutic Areas
Disease areas where VIELA BIO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
VIELA BIO Pipeline Snapshot
Active clinical trials for VIELA BIO across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • UPLIZNA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-06-11
- Latest
- 2025-12-11
- Applications
- 1